95 related articles for article (PubMed ID: 17301952)
1. JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response.
Tao J; Gao Y; Li MO; He W; Chen L; Harvev B; Davis RJ; Flavell RA; Yin Z
Eur J Immunol; 2007 Mar; 37(3):818-29. PubMed ID: 17301952
[TBL] [Abstract][Full Text] [Related]
2. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses.
Zhu Y; Ju S; Chen E; Dai S; Li C; Morel P; Liu L; Zhang X; Lu B
J Immunol; 2010 Sep; 185(6):3174-83. PubMed ID: 20713880
[TBL] [Abstract][Full Text] [Related]
3. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
5. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.
Hegel JK; Knieke K; Kolar P; Reiner SL; Brunner-Weinzierl MC
Eur J Immunol; 2009 Mar; 39(3):883-93. PubMed ID: 19224637
[TBL] [Abstract][Full Text] [Related]
6. Redox modulation inhibits CD8 T cell effector function.
Sklavos MM; Tse HM; Piganelli JD
Free Radic Biol Med; 2008 Nov; 45(10):1477-86. PubMed ID: 18805480
[TBL] [Abstract][Full Text] [Related]
7. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation.
Ohnishi H; Takeda K; Domenico J; Lucas JJ; Miyahara N; Swasey CH; Dakhama A; Gelfand EW
J Allergy Clin Immunol; 2009 Jan; 123(1):249-57. PubMed ID: 19130938
[TBL] [Abstract][Full Text] [Related]
9. Control of effector CD8+ T cell function by the transcription factor Eomesodermin.
Pearce EL; Mullen AC; Martins GA; Krawczyk CM; Hutchins AS; Zediak VP; Banica M; DiCioccio CB; Gross DA; Mao CA; Shen H; Cereb N; Yang SY; Lindsten T; Rossant J; Hunter CA; Reiner SL
Science; 2003 Nov; 302(5647):1041-3. PubMed ID: 14605368
[TBL] [Abstract][Full Text] [Related]
10. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
13. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
[TBL] [Abstract][Full Text] [Related]
14. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
15. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
[TBL] [Abstract][Full Text] [Related]
16. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
17. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation.
Cottalorda A; Verschelde C; Marçais A; Tomkowiak M; Musette P; Uematsu S; Akira S; Marvel J; Bonnefoy-Berard N
Eur J Immunol; 2006 Jul; 36(7):1684-93. PubMed ID: 16761317
[TBL] [Abstract][Full Text] [Related]
18. B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses.
Wahl C; Bochtler P; Chen L; Schirmbeck R; Reimann J
Gastroenterology; 2008 Sep; 135(3):980-8. PubMed ID: 18621049
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Gancz D; Donin N; Fishelson Z
Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
